Opportunity Information: Apply for CDC RFA PS21 2103
The Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments opportunity (CDC RFA PS21-2103) is a CDC cooperative agreement designed to strengthen and better coordinate viral hepatitis surveillance and prevention work across U.S. states and large local jurisdictions. It focuses on building integrated programs that can both detect hepatitis trends quickly and translate that information into practical prevention and care strategies. The overarching goal is to help health departments move toward viral hepatitis elimination by improving how they plan for outbreaks, collect and use surveillance data, and connect people at highest risk to testing, treatment, and preventive services.
A central emphasis of the program is improving surveillance and readiness for response. Funded jurisdictions are expected to enhance outbreak planning and response capacity for viral hepatitis and to strengthen surveillance for acute hepatitis A, hepatitis B, and hepatitis C, along with chronic hepatitis C. In practice, this means improving the ability to identify new infections, detect clusters and outbreaks earlier, and ensure that case reporting and public health follow-up are complete and timely. The opportunity also calls for more comprehensive hepatitis B and C reporting, reflecting a priority on higher-quality data that can guide decisions, measure progress, and identify gaps in prevention and care.
Another major requirement is for recipients to develop a jurisdictional viral hepatitis elimination plan. This plan is meant to be more than a document; it is intended to drive coordinated action and stronger partnerships. Health departments are expected to increase stakeholder engagement in elimination planning, bringing together clinical providers, community organizations, correctional health partners, substance use services, and other key groups to align strategies. The program also prioritizes improving HBV and HCV testing efforts and expanding the number of healthcare providers trained to treat hepatitis B and hepatitis C, which supports longer-term capacity to diagnose and treat more people rather than relying on a small subset of specialists.
If additional funding is available, the NOFO describes expanded activities that can be supported. These include adding or enhancing surveillance for chronic hepatitis B and perinatal hepatitis C, which would help jurisdictions understand ongoing transmission patterns and improve prevention efforts for infants and families. It also includes increasing hepatitis B and C testing and referral to care in high-impact settings where risk and missed opportunities for diagnosis are often concentrated. Examples named in the opportunity include syringe services programs, substance use disorder treatment centers, correctional facilities, emergency departments, and sexually transmitted disease clinics. The intent is to place testing and linkage-to-care pathways in locations where people are more likely to be reached, especially those who may not have regular access to primary care.
The NOFO also highlights the importance of preventing viral hepatitis and other infections among people who inject drugs. Contingent on funding, jurisdictions can support efforts that expand access to prevention services for PWID, recognizing the overlapping risks for hepatitis and other infectious diseases and the value of providing practical, low-barrier services in community settings. Additionally, an optional component (also contingent on funding) would support improved access to prevention, diagnosis, and treatment for viral, bacterial, and fungal infections related to drug use in settings disproportionately affected by drug use. This optional element reflects a broader public health approach that addresses co-occurring infectious disease needs rather than treating hepatitis in isolation.
The expected outcomes of the program are framed around measurable improvements in public health capacity and service access. CDC anticipates stronger viral hepatitis surveillance systems, more meaningful stakeholder engagement tied to elimination planning, and improved access to prevention, diagnosis, and treatment services for populations most at risk. In short, the opportunity is structured to help health departments detect hepatitis more effectively, respond faster, plan collaboratively for elimination, and expand testing and care connections in the settings where they can have the greatest impact.
Administratively, this is a discretionary funding opportunity offered by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (NCHHSTP), using a cooperative agreement mechanism. Eligible applicants include state governments and local governments (counties, cities or townships) as well as special district governments. The opportunity was created on August 25, 2020, with an original application deadline of December 1, 2020 (applications due by 11:59 p.m. Eastern Time). CDC anticipated making 58 awards. The listing includes an award ceiling of 0, which typically indicates the ceiling was not specified in the summary data rather than implying no funding would be provided.Apply for CDC RFA PS21 2103
- The Department of Health and Human Services, Centers for Disease Control - NCHHSTP in the health sector is offering a public funding opportunity titled "Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.270.
- This funding opportunity was created on Aug 25, 2020.
- Applicants must submit their applications by Dec 01, 2020 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 58 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments opportunity?
It is a CDC cooperative agreement (RFA PS21-2103) designed to strengthen and better coordinate viral hepatitis surveillance and prevention work across U.S. states and large local jurisdictions. The program emphasizes integrated approaches that can quickly detect hepatitis trends and turn those findings into practical prevention and care strategies.
What is the main goal of this CDC cooperative agreement?
The overarching goal is to help health departments move toward viral hepatitis elimination by improving outbreak planning, strengthening surveillance data collection and use, and better connecting people at highest risk to testing, treatment, and preventive services.
Who is the funding intended to support?
The opportunity is designed for health departments in U.S. states and large local jurisdictions, with eligible applicants including state governments and local governments (counties, cities, or townships), as well as special district governments.
Which agency and department are offering this funding?
This is a discretionary funding opportunity offered by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), within NCHHSTP.
What type of funding mechanism is used?
The award is structured as a cooperative agreement, which generally indicates substantial involvement by the funding agency in the funded work compared to some other award types.
What viral hepatitis conditions are emphasized for surveillance under this opportunity?
Funded jurisdictions are expected to strengthen surveillance for acute hepatitis A, acute hepatitis B, acute hepatitis C, and chronic hepatitis C. The opportunity also calls for more comprehensive hepatitis B and C reporting to improve data quality and usefulness.
What does the opportunity require related to outbreak planning and response?
A central emphasis is improving surveillance and readiness for response. Recipients are expected to enhance outbreak planning and response capacity for viral hepatitis, including improving the ability to identify new infections, detect clusters and outbreaks earlier, and ensure case reporting and public health follow-up are complete and timely.
What is meant by building an "integrated" viral hepatitis program?
Based on the NOFO description, integration refers to strengthening and coordinating surveillance and prevention so that jurisdictions can detect hepatitis trends quickly and translate surveillance findings into real-world prevention and care strategies.
What is a jurisdictional viral hepatitis elimination plan, and is it required?
Recipients are expected to develop a jurisdictional viral hepatitis elimination plan. The plan is intended to drive coordinated action rather than serve as a stand-alone document, and it is meant to strengthen partnerships and align strategies across key stakeholders.
What kinds of stakeholders are expected to be engaged in elimination planning?
The opportunity highlights increasing stakeholder engagement by bringing together partners such as clinical providers, community organizations, correctional health partners, substance use services, and other key groups to align strategies for elimination.
How does the program address hepatitis B and hepatitis C testing?
The program prioritizes improving HBV and HCV testing efforts, including expanding the number of healthcare providers trained to treat hepatitis B and hepatitis C. This is intended to build longer-term capacity to diagnose and treat more people rather than relying on a small number of specialists.
What does the NOFO say about training healthcare providers?
It prioritizes expanding the number of healthcare providers trained to treat hepatitis B and hepatitis C to support broader treatment capacity over time.
Are there activities that are only supported if additional funding is available?
Yes. The NOFO describes expanded activities that can be supported contingent on additional funding being available.
What expanded surveillance activities may be supported if additional funding is available?
Contingent on additional funding, jurisdictions may add or enhance surveillance for chronic hepatitis B and perinatal hepatitis C to better understand transmission patterns and strengthen prevention efforts for infants and families.
What high-impact settings are identified for expanded testing and referral activities (if funded)?
If additional funding is available, the NOFO describes increasing hepatitis B and C testing and referral to care in high-impact settings, including syringe services programs, substance use disorder treatment centers, correctional facilities, emergency departments, and sexually transmitted disease clinics.
Why does the opportunity emphasize high-impact settings for testing and linkage to care?
The intent is to place testing and linkage-to-care pathways in locations where risk and missed opportunities for diagnosis are often concentrated, especially where people may be less likely to have regular access to primary care.
How does the opportunity address prevention among people who inject drugs (PWID)?
Contingent on funding, jurisdictions can support efforts that expand access to prevention services for people who inject drugs, recognizing overlapping risks for hepatitis and other infectious diseases and the value of low-barrier, practical services in community settings.
Is there an optional component described in the NOFO?
Yes. An optional component (also contingent on funding) would support improved access to prevention, diagnosis, and treatment for viral, bacterial, and fungal infections related to drug use in settings disproportionately affected by drug use.
What is the public health rationale for the optional drug use-related infections component?
The optional element reflects a broader approach that addresses co-occurring infectious disease needs rather than treating hepatitis in isolation, particularly in settings heavily affected by drug use.
What outcomes does CDC expect from this program?
Expected outcomes include stronger viral hepatitis surveillance systems, more meaningful stakeholder engagement tied to elimination planning, and improved access to prevention, diagnosis, and treatment services for populations most at risk.
How many awards did CDC anticipate making under this opportunity?
CDC anticipated making 58 awards.
When was this opportunity created, and what was the application deadline?
The listing notes the opportunity was created on August 25, 2020, with an original application deadline of December 1, 2020 (applications due by 11:59 p.m. Eastern Time).
What does it mean that the award ceiling is listed as 0?
The listing explains that an award ceiling of 0 typically indicates the ceiling was not specified in the summary data, rather than implying that no funding would be provided.
Does the NOFO focus only on surveillance, or also on prevention and care connections?
It covers both. While surveillance and readiness are central, the opportunity also emphasizes translating surveillance data into prevention and care strategies, expanding testing, strengthening referral to care, and improving access to treatment and preventive services for those at highest risk.
Which hepatitis reporting improvements are highlighted?
The opportunity calls for more comprehensive hepatitis B and C reporting, reflecting a priority on higher-quality data to guide decisions, measure progress, and identify gaps in prevention and care.
What does "complete and timely" follow-up refer to in this program?
In the context provided, it refers to ensuring case reporting and public health follow-up are conducted fully and without unnecessary delays, supporting earlier cluster detection and faster response.
Browse more opportunities from the same category: Health
Next opportunity: Maternal and Child Health (MCH) Leadership, Education, and Advancement in Undergraduate Pathways (LEAP) Training Program
Previous opportunity: Accelerating and Expanding LOINC® Development to Support Public Health Needs
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS21 2103
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS21 2103) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIOSH Centers of Excellence for Total Worker Health® (U19) Apply for PAR 20 297 Funding Number: PAR 20 297 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,400,000 |
| National Community Anti-drug Coalition Institute Apply for DFCNCI 2020 Funding Number: DFCNCI 2020 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $2,500,000 |
| Strengthening the Nation's Public Health Communication Infrastructure to Respond to COVID-19 Apply for CDC RFA CD20 2001 Funding Number: CDC RFA CD20 2001 Agency: Department of Health and Human Services, Centers for Disease Control - OD Category: Health Funding Amount: $500,000 |
| Study to Explore Early Development (SEED) Follow up Studies Apply for RFA DD 21 001 Funding Number: RFA DD 21 001 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,560,000 |
| National Foundation for the Centers for Disease Control and Prevention Apply for CDC RFA CD21 2101 Funding Number: CDC RFA CD21 2101 Agency: Department of Health and Human Services, Centers for Disease Control - OD Category: Health Funding Amount: $1,250,000 |
| Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant Apply for HRSA 21 013 Funding Number: HRSA 21 013 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| HUD FY2020 Healthy Homes and Weatherization Cooperation Demonstration Apply for FR 6400 N 62 Funding Number: FR 6400 N 62 Agency: US Department of Housing and Urban Development Category: Health Funding Amount: $1,000,000 |
| Community Health Access and Rural Transformation (CHART) Apply for CMS 2G2 21 001 Funding Number: CMS 2G2 21 001 Agency: Department of Health and Human Services, Centers for Medicare Medicaid Services Category: Health Funding Amount: $5,000,000 |
| Rural Health Research Dissemination Program Apply for HRSA 21 025 Funding Number: HRSA 21 025 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $145,000 |
| Comprehensive High-Impact HIV Prevention Programs for Community-Based Organizations Apply for CDC RFA PS21 2102 Funding Number: CDC RFA PS21 2102 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Thalassemia Program Apply for HRSA 21 035 Funding Number: HRSA 21 035 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $175,000 |
| Global TravEpiNet (GTEN): The Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs Apply for RFA CK 21 001 Funding Number: RFA CK 21 001 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,500,000 |
| Military Specific HIV/AIDS Prevention, Care, and Treatment Program for PEPFAR (President’s Emergency Plan for AIDS Relief) Apply for W81XWH 21 DHAPP Funding Number: W81XWH 21 DHAPP Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Health Funding Amount: Case Dependent |
| Monitoring Cause-specific School Absenteeism for Estimating Community-wide Influenza and SARS-CoV-2 Transmission Apply for RFA CK 21 003 Funding Number: RFA CK 21 003 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,000,000 |
| Rural Health Care Services Outreach Program Apply for HRSA 21 027 Funding Number: HRSA 21 027 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Implementing and Evaluating a Data-to-Care Rx Strategy Apply for RFA PS 21 004 Funding Number: RFA PS 21 004 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $595,333 |
| Emerging Infections Network - Research for Preventing, Detecting, and Managing Travelers who Acquire Infectious Diseases Abroad Apply for RFA CK 21 002 Funding Number: RFA CK 21 002 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $1,500,000 |
| State Occupational Safety and HealthSurveillance Program (U60) Apply for PAR 20 312 Funding Number: PAR 20 312 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $140,000 |
| Cooperative Research Agreements Related to the World Trade Center Health Program (U01) Apply for PAR 20 280 Funding Number: PAR 20 280 Agency: Department of Health and Human Services, Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $600,000 |
| Advancing Population-Based Surveillance of Birth Defects Apply for CDC RFA DD21 2101 Funding Number: CDC RFA DD21 2101 Agency: Department of Health and Human Services, Centers for Disease Control - NCBDDD Category: Health Funding Amount: $325,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS21 2103", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.